Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
Sequana-Medical-NV-Consolidated-Accounts-31-12-22-NL.pdf
Audit Report / Information Classification · 100% confidence The document is a formal 'Commissarisverslag' (Auditor's Report) for Sequana Medical NV regarding the consolidated financial statements for the fiscal year ending December 31, 2022. It contains the auditor's opinion, key audit matters (such as the Kreos loan agreement), and descriptions of the auditor's responsibilities. As it is a standalone audit report and not the full annual report itself, it falls under the 'Audit Report / Information' category. FY 2022
2023-04-25 Dutch
Sequana-Medical-7-228-Board-Report-NL-final.pdf
Management Reports Classification · 99% confidence The document is titled "Verslag van de raad van bestuur overeenkomstig artikel 7:228 van het Wetboek van vennootschappen en verenigingen" (Report of the board of directors pursuant to Article 7:228 of the Code of Companies and Associations). This article mandates a report when the net assets fall below 50% or 25% of the capital, requiring a decision on dissolution or other measures at a general shareholders' meeting. The text details the calculation of the negative net assets as of December 31, 2022, references the upcoming General Shareholders' Meeting (GAV) on May 25, 2023, and outlines the Board's proposed measures (including recent capital raising and cost-cutting) to ensure continuity, explicitly asking shareholders not to dissolve the company. This content strongly aligns with the requirements for a report concerning board/management actions and governance related to financial distress or capital structure, which is often presented to shareholders ahead of a meeting. While it discusses financial results (like an IR or MDA), its primary function, dictated by the Belgian corporate law article cited, is to report the board's findings and recommendations regarding the company's solvency status to the shareholders for a vote. Given the options, 'Board/Management Information' (MANG) covers announcements of board actions and recommendations, and 'Governance Information' (CGR) covers internal rules and board structure. However, the specific context of reporting on capital impairment under Belgian law, often leading to a special resolution or an EGM/AGM discussion, makes it a critical piece of management reporting related to corporate structure and governance. Since it is a formal report from the Board detailing financial status and proposing actions (including cost-cutting and financing strategy), it fits best under Management Reports (MDA) or Board/Management Information (MANG). Given the focus on the Board's assessment and proposed measures following a financial trigger, MANG is a strong fit, as is MDA. Since the document is a formal report detailing the financial situation and management's proposed path forward, MDA (Management's detailed explanation of financial results, business trends, and outlook) is highly appropriate. However, the document is specifically a 'Report of the board of directors' mandated by law regarding capital maintenance, which is a core governance/board function. Comparing MANG (Board changes) and MDA (Financial explanation), this document is more about the Board's official assessment and proposed strategy to address the financial situation than a standard earnings explanation. Let's re-evaluate based on the definitions. It is not an ER, IR, or 10-K. It is a formal report detailing the Board's required action due to capital impairment. This type of statutory report detailing the financial health and proposed continuation strategy is often categorized under Governance or Management Analysis. Given the detailed analysis of the balance sheet and future strategy/cost-cutting, MDA is the most encompassing category for management's detailed explanation of financial results and outlook/strategy. If it were purely about board composition, MANG would fit. If it were about shareholder voting materials, PSI would fit. MDA covers the detailed explanation of financial results and outlook, which this document provides extensively.
2023-04-25 Dutch
230420-Board-Report-Statutory-Accounts-FY2022-1-NL-final.pdf
Annual Report Classification · 100% confidence The document is a 'Jaarverslag van de Raad van Bestuur' (Annual Report of the Board of Directors) for Sequana Medical NV for the fiscal year ending December 31, 2022. It contains detailed financial statements, balance sheets, income statements, management analysis of financial results, and notes on the company's going concern status. As it provides comprehensive financial data and analysis for the full fiscal year, it is classified as an Annual Report (10-K equivalent in this context). FY 2022
2023-04-25 Dutch
1 -- Convening Notice (final) (NL).pdf
AGM Information Classification · 100% confidence The document is explicitly titled "UITNODIGING GEWONE ALGEMENE AANDEELHOUDERSVERGADERING" (Invitation to the Ordinary General Shareholders' Meeting) and details the date, time, location, and agenda for this meeting scheduled for May 25, 2023. The agenda items cover standard AGM topics like approving annual accounts, granting discharge, and discussing remuneration reports. This content perfectly matches the definition of AGM Information. Although it mentions annual accounts (related to 10-K/AR), the primary purpose and format of this document is the formal notice and agenda for the shareholder meeting itself, not the full financial report or the audit report. Therefore, the correct classification is AGM-R.
2023-04-25 Dutch
5 -- Overview of Voting Rigths (final).pdf
AGM Information Classification · 98% confidence The document is titled 'AANTAL AANDELEN EN STEMRECHTEN GEWONE ALGEMENE VERGADERING' (Outstanding Shares and Voting Rights Ordinary General Meeting) and specifies the date of the meeting (May 25, 2023). It details the total number of outstanding shares and potential shares issuable upon exercise of options/warrants, which is information directly related to shareholder rights and the structure for voting at a general meeting. This content strongly aligns with the purpose of an Annual General Meeting (AGM) or related preparatory/disclosure documents. Since it provides the official share count used for voting rights calculation ahead of the AGM, it fits best under AGM Information (AGM-R). It is not a full financial report (10-K or IR), a management change announcement (MANG), or a proxy statement (PSI), but rather specific data supporting the AGM process.
2023-04-25 Dutch
4 -- Vote by Mail Form (final) (NL ENG).pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is explicitly titled 'FORMULIER VOOR STEMMING PER BRIEF' (VOTE BY MAIL FORM) for the 'GEWONE ALGEMENE VERGADERING' (ORDINARY GENERAL MEETING) scheduled for May 25, 2023. This form is used by shareholders to cast their votes on the agenda items (which include approval of the 2022 financial statements and discharge of directors) prior to the meeting. This material is directly related to soliciting and recording shareholder votes for an AGM, fitting the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to request votes. While it relates to the AGM, it is the voting mechanism itself, not the AGM presentation (AGM-R) or the final voting results (DVA).
2023-04-25 Dutch

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.